finanzwire.de

Search

POLYPHOR AG EQS-News: Polyphor announces two oral and six poster presentations plus a press conference at the 27th ECCMID Congress, Vienna

Transparenzrichtlinie : geregelte Berichte

20/04/2017 13:33

24/04/2017 18:15
20/04/2017 13:33
09/02/2017 09:00
18/10/2016 14:07

EQS Group-News: Polyphor AG / Schlagwort(e): Konferenz
Polyphor announces two oral and six poster presentations plus a press conference at the 27th ECCMID Congress, Vienna

20.04.2017 / 13:33


Polyphor announces two oral and six poster presentations plus a press conference at the 27th ECCMID Congress, Vienna


Allschwil, Switzerland, 20 April, 2017. Polyphor announces today its presence at ECCMID with two oral and six poster presentations on Murepavadin (POL7080) and POL7001 as well as a press conference.

Dr Glenn Dale, Head of Early Development, Antimicrobials, Polyphor, and Dr Anouk Muller, Medical Microbiology, Medisch Centrum Haaglanden, The Hague, will give two oral presentations illustrating new data for Murepavadin (POL7080), a novel Pseudomonas specific antibiotic being developed for nosocomial pneumonia.

- Pharmacokinetics and pharmacodynamics of Murepavadin (POL7080) in neutropenic lung infection models

- Population pharmacokinetics of Murepavadin (POL7080) and Monte Carlo simulations to develop clinical dosing regimens, including the renally impaired


The presentations will take place during the session OS201: PK/PD: "What you need to learn from new and old-revived antibiotics" on Tuesday 25th April, at 13.30-15.30 CET in Hall K.

In addition, five poster presentations on Murepavadin (POL7080) and one on POL7001 will take place on Monday 24th April at 12.30- 13.30 CET, sessions PO063 and PO068.

- In vitro drug transporter interaction studies with the outer membrane protein targeting antibiotic Murepavadin (POL7080): Poster 2822

- Catabolism and Excretion of the Anti-Pseudomonal Peptidomimetic Murepavadin (POL7080) in Humans: Poster 2748

- Population pharmacokinetics modeling of Murepavadin (POL7080) and simulation of target attainment in a population with ventilator-associated pneumonia due to infection with Pseudomonas Aeruginosa: Poster 2729

- Pharmacokinetic and efficacy analysis of Murepavadin (POL7080) co-administered with standard-of-care (SoC) in a phase II study in patients with ventilator-associated pneumonia (VAP) due to suspected or documented Pseudomonas Aeruginosa infection: Poster 2720

- Pharmacokinetics of Murepavadin (POL7080) and amikacin in a drug‐drug interaction study in healthy subjects: Poster 2670

- POL7001 is highly efficacious in the murine neutropenic lung infection model: Poster 2708


In addition, Polyphor will hold, a press conference, 'New hope in the battle against antibiotic resistance - addressing a healthcare emergency', on Monday 24th April, 18:15-19:15 CET at Room Krieau 2, Courtyard by Marriott Vienna Prater/Messe, Trabrennstraße 4, 1020, Vienna.

 

Dr. Glenn Dale stated "We are pleased to have a significant presence at ECCMID, a prestigious congress. We look forward to sharing new data with our colleagues from across the globe and to demonstrate our commitment to addressing pseudomonas infections and antibiotic resistance, one of the most serious health threats of our time."


About Polyphor

Polyphor is a clinical stage, privately held Swiss specialty pharma company, focused on the development of macrocycle drugs that address antibiotic resistance and severe respiratory diseases. The company's lead drug candidates include:

- Murepavadin (POL7080, in Phase II entering Phase III / Pivotal registration program), a precision Outer Membrane Protein Targeting Antibiotic (OMPTA) against Pseudomonas Aeruginosa.

- POL6014 (in Phase Ib), an inhaled inhibitor of neutrophil elastase for the treatment of cystic fibrosis and other severe lung diseases.

- Balixafortide (POL6326, in Phase Ib), an antagonist of the chemokine receptor CXCR4 for combination treatment in oncology.

Polyphor has discovered the OMPTA class and is further developing it, including a broad-spectrum preclinical candidate, to address infections caused by difficult-to-treat, resistant Gram-negative pathogens - one of the most pressing emerging medical needs. The OMPTA represent the first new class of antibiotics against Gram-negative bacteria reaching advanced clinical stage in the last 40 years.

In addition, Polyphor has an important activity of discovery technology partnerships to assist pharma companies in research programs addressing difficult targets through its proprietary macrocycle technology platform.

Polyphor has several industry partnerships with and financing from the Cystic Fibrosis Foundation Therapeutics, Gilead Sciences, Novartis, Taisho and the Wellcome Trust.

Contact:

Catherine Hof
Corporate Communications
Polyphor Ltd
Tel: +41 61 567 16 00
Email: PR@polyphor.com
Jo Hewitt
Director
HAVAS Just::
Tel: +44 208 877 8421
Email: jo@justhealthcomms.com

Zusatzmaterial zur Meldung:

Dokument: http://n.eqs.com/c/fncls.ssp?u=KTEEAJNCMN
Dokumenttitel: Poyphor_ECCM Congress


Ende der Medienmitteilung


565917  20.04.2017 

fncls.ssp?fn=show_t_gif&application_id=565917&application_name=news&site_id=symex